Cytokinetics (CYTK) Stock Forecast & Price Target

Compare

1,210 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CYTK Analyst Ratings

Strong Buy

15 Buy

2 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Cytokinetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CYTK Stock 12 Month Forecast

Average Price Target

$88.00

▲(34.15% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $88.00 with a high forecast of $136.00 and a low forecast of $61.00. The average price target represents a 34.15% change from the last price of $65.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","137":"$137","56.75":"$56.8","83.5":"$83.5","110.25":"$110.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$136.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$88.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$61.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,56.75,83.5,110.25,137],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.05,71.43076923076923,76.81153846153846,82.1923076923077,87.57307692307693,92.95384615384616,98.33461538461538,103.71538461538461,109.09615384615384,114.47692307692307,119.8576923076923,125.23846153846154,130.61923076923077,{"y":136,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.05,67.73846153846154,69.42692307692307,71.11538461538461,72.80384615384615,74.49230769230769,76.18076923076923,77.86923076923077,79.5576923076923,81.24615384615385,82.93461538461538,84.62307692307692,86.31153846153846,{"y":88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.05,65.66153846153846,65.27307692307691,64.88461538461539,64.49615384615385,64.1076923076923,63.71923076923077,63.33076923076923,62.94230769230769,62.55384615384615,62.16538461538462,61.776923076923076,61.38846153846154,{"y":61,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":50.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.21,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.84,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$136.00

Average Price Target$88.00

Lowest Price Target$61.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Srikripa Devarakonda

Truist Financial

$70→$84

Buy

28.05%

Upside

Reiterated

12/23/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN), Fortrea Holdings Inc. (NASDAQ: FTRE) and Cytokinetics (NASDAQ: CYTK)

Yasmeen Rahimi

Piper Sandler

$107

Buy

63.11%

Upside

Reiterated

12/22/25

Cytokinetics (CYTK) Gets a Buy from Piper Sandler

Cory Kasimov

Evercore ISI

$80

Buy

21.95%

Upside

Reiterated

12/22/25

Cytokinetics (CYTK) Receives a Buy from Evercore ISI

Jason Butler

Citizens JMP

$78→$88

Buy

34.15%

Upside

Reiterated

12/22/25

Cytokinetics price target raised to $88 from $78 at CitizensCytokinetics price target raised to $88 from $78 at Citizens

Serge Belanger

Needham

$72→$84

Buy

28.05%

Upside

Reiterated

12/22/25

Cytokinetics (CYTK): Myqorzo’s Differentiated Profile, Global Upside, and Pipeline Catalysts Support Raised Target and Buy Rating

Jason Zemansky

Bank of America Securities

$63→$64

Hold

-2.44%

Downside

Reiterated

12/22/25

Cytokinetics price target raised to $64 from $63 at BofACytokinetics price target raised to $64 from $63 at BofA

Joseph Pantginis

H.C. Wainwright

$120→$136

Buy

107.32%

Upside

Reiterated

12/22/25

Cytokinetics price target raised to $136 from $120 at H.C. WainwrightCytokinetics price target raised to $136 from $120 at H.C. Wainwright

Maxwell Skor

Morgan Stanley

$65→$71

Buy

8.23%

Upside

Reiterated

12/22/25

Cytokinetics price target raised to $71 from $65 at Morgan StanleyCytokinetics price target raised to $71 from $65 at Morgan Stanley

James Condulis

Stifel Nicolaus

$95

Buy

44.82%

Upside

Assigned

12/22/25

Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cytokinetics (NASDAQ: CYTK)

Roanna Ruiz

Leerink Partners

$73→$83

Buy

26.52%

Upside

Reiterated

12/22/25

Cytokinetics price target raised to $83 from $73 at LeerinkCytokinetics price target raised to $83 from $73 at Leerink

Gena Wang

Barclays

$82→$87

Buy

32.62%

Upside

Reiterated

12/21/25

Barclays Remains a Buy on Cytokinetics (CYTK)

Kenneth Herbert

RBC Capital

$87→$95

Buy

44.82%

Upside

Reiterated

12/19/25

RBC Capital Sticks to Its Buy Rating for Cytokinetics (CYTK)

Tessa Romero

J.P. Morgan

Buy

―

Reiterated

12/19/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amicus (NASDAQ: FOLD), Merck & Company (NYSE: MRK) and Cytokinetics (NASDAQ: CYTK)

Paul Choi

Goldman Sachs

$95

Buy

44.82%

Upside

Upgraded

12/18/25

Cytokinetics upgraded to Buy from Neutral at Goldman SachsCytokinetics upgraded to Buy from Neutral at Goldman Sachs

Ashwani Verma

UBS

$41→$61

Hold

-7.01%

Downside

Reiterated

12/02/25

Analysts Conflicted on These Healthcare Names: Cytokinetics (NASDAQ: CYTK) and CVS Health (NYSE: CVS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Srikripa Devarakonda

Truist Financial

$70→$84

Buy

28.05%

Upside

Reiterated

12/23/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN), Fortrea Holdings Inc. (NASDAQ: FTRE) and Cytokinetics (NASDAQ: CYTK)

Yasmeen Rahimi

Piper Sandler

$107

Buy

63.11%

Upside

Reiterated

12/22/25

Cytokinetics (CYTK) Gets a Buy from Piper Sandler

Cory Kasimov

Evercore ISI

$80

Buy

21.95%

Upside

Reiterated

12/22/25

Cytokinetics (CYTK) Receives a Buy from Evercore ISI

Jason Butler

Citizens JMP

$78→$88

Buy

34.15%

Upside

Reiterated

12/22/25

Cytokinetics price target raised to $88 from $78 at CitizensCytokinetics price target raised to $88 from $78 at Citizens

Serge Belanger

Needham

$72→$84

Buy

28.05%

Upside

Reiterated

12/22/25

Cytokinetics (CYTK): Myqorzo’s Differentiated Profile, Global Upside, and Pipeline Catalysts Support Raised Target and Buy Rating

Jason Zemansky

Bank of America Securities

$63→$64

Hold

-2.44%

Downside

Reiterated

12/22/25

Cytokinetics price target raised to $64 from $63 at BofACytokinetics price target raised to $64 from $63 at BofA

Joseph Pantginis

H.C. Wainwright

$120→$136

Buy

107.32%

Upside

Reiterated

12/22/25

Cytokinetics price target raised to $136 from $120 at H.C. WainwrightCytokinetics price target raised to $136 from $120 at H.C. Wainwright

Maxwell Skor

Morgan Stanley

$65→$71

Buy

8.23%

Upside

Reiterated

12/22/25

Cytokinetics price target raised to $71 from $65 at Morgan StanleyCytokinetics price target raised to $71 from $65 at Morgan Stanley

James Condulis

Stifel Nicolaus

$95

Buy

44.82%

Upside

Assigned

12/22/25

Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cytokinetics (NASDAQ: CYTK)

Roanna Ruiz

Leerink Partners

$73→$83

Buy

26.52%

Upside

Reiterated

12/22/25

Cytokinetics price target raised to $83 from $73 at LeerinkCytokinetics price target raised to $83 from $73 at Leerink

Gena Wang

Barclays

$82→$87

Buy

32.62%

Upside

Reiterated

12/21/25

Barclays Remains a Buy on Cytokinetics (CYTK)

Kenneth Herbert

RBC Capital

$87→$95

Buy

44.82%

Upside

Reiterated

12/19/25

RBC Capital Sticks to Its Buy Rating for Cytokinetics (CYTK)

Tessa Romero

J.P. Morgan

Buy

―

Reiterated

12/19/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amicus (NASDAQ: FOLD), Merck & Company (NYSE: MRK) and Cytokinetics (NASDAQ: CYTK)

Paul Choi

Goldman Sachs

$95

Buy

44.82%

Upside

Upgraded

12/18/25

Cytokinetics upgraded to Buy from Neutral at Goldman SachsCytokinetics upgraded to Buy from Neutral at Goldman Sachs

Ashwani Verma

UBS

$41→$61

Hold

-7.01%

Downside

Reiterated

12/02/25

Analysts Conflicted on These Healthcare Names: Cytokinetics (NASDAQ: CYTK) and CVS Health (NYSE: CVS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

1 Month

xxx

Success Rate

14/20 ratings generated profit

Average Return

+15.70%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +15.70% per trade.

3 Months

xxx

Success Rate

11/20 ratings generated profit

Average Return

+27.80%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.00% of your transactions generating a profit, with an average return of +27.80% per trade.

1 Year

Joseph PantginisH.C. Wainwright

Success Rate

13/18 ratings generated profit

Average Return

+23.32%

reiterated a buy rating 2 days ago

Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 72.22% of your transactions generating a profit, with an average return of +23.32% per trade.

2 Years

xxx

Success Rate

16/18 ratings generated profit

Average Return

+33.61%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +33.61% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CYTK Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CYTK has received 30 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. CYTK average Analyst price target in the past 3 months is 88.00.

Each month's total comprises the sum of three months' worth of ratings.

CYTK Financial Forecast

CYTK Earnings Forecast

Next quarter’s earnings estimate for CYTK is -$1.55 with a range of -$2.14 to -$1.26. The previous quarter’s EPS was -$2.55. CYTK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.

CYTK Sales Forecast

Next quarter’s sales forecast for CYTK is $7.12M with a range of $0.00 to $30.00M. The previous quarter’s sales results were $1.94M. CYTK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.

CYTK Stock Forecast FAQ

What is CYTK’s average 12-month price target, according to analysts?

Based on analyst ratings, Cytokinetics’s 12-month average price target is 88.00.

What is CYTK’s upside potential, based on the analysts’ average price target?

Cytokinetics has 34.15% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CYTK a Buy, Sell or Hold?

Cytokinetics has a consensus rating of Strong Buy which is based on 15 buy ratings, 2 hold ratings and 0 sell ratings.

What is Cytokinetics’s price target?

The average price target for Cytokinetics is 88.00. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $136.00 ,the lowest forecast is $61.00. The average price target represents 34.15% Increase from the current price of $65.6.

What do analysts say about Cytokinetics?

Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of CYTK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Cytokinetics (CYTK) Stock Forecast & Price Target

CYTK Analyst Ratings

CYTK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cytokinetics

CYTK Analyst Recommendation Trends

CYTK Financial Forecast

CYTK Earnings Forecast

CYTK Sales Forecast

CYTK Stock Forecast FAQ

Detailed List of Analyst Forecasts